But Clorox isn't Mickelson's only stock holding. His portfolio includes five companies for which he does endorsements.
I doubt the three-time Masters Champ (2004, 2006 & 2010), PGA Champion (2005) and the British Open winner (2013) will lose one dime of endorsement dollars. The $180 million golf champ getting ready for the U.S. Open Championship match on June 12 in Pinehurst, North Carolina.
Here are the components in the Phil Mickelson portfolio.
Clorox (CLX) ($88.59) set an all-time intraday high at $96.76 but I wonder whether or not Phil washed his hands of this company. The stock is just above its 200-day simple moving average at $88.10.
The weekly chart is negative given a close this week below its five-week modified moving average at $88.39 which indicates risk to its 200-week simple moving average at $75.32. Annual value levels are $84.10 and $74.09 with semiannual pivots at $86.84 and $88.73 and quarterly risky level at $95.67. This profile suggests that if Phil still owns the stock its time to sell.
Callaway Golf (ELY) ($7.89) is Phil's most important endorsement as he must use Callaway products. If Phil can keep the ball in the fairway with his Big Bertha driver he will win the U.S. Open on June 15. If he misses the fairway he's still the best on the PGA Tour with those short-wedge shots. His biggest issue that could prevent winning is missing short putts, which has been his Achilles Heel in many majors. Despite the cloud of his 2011 Clorox trade the odds of Mickelson win is 14 to 1.
The stock set a multiyear intraday high at $10.35 on April 1 and is now below its 200-day SMA at $8.25 with its 2014 intraday low set at $7.51 on May 20. The weekly chart is negative with its five-week MMA at $8.41 and its 200-week SMA at $6.87. An annual value level is $6.73 with a semiannual risky level at $8.45. Buy the clubs, not the stock.
Amgen (AMGN) ($119.12) and Pfizer (PFE) (29.56) jointly market Enbrel the drug Phil uses to treat his symptoms of psoriatic arthritis. Amgen is trading above its 200-day SMA at $116.01 after setting an all-time high at $128.96 on march 21. Pfizer is trading below its 200-day SMA at $30.47 after setting a multiyear intraday high at $32.96 on March 6.
Amgen has a positive weekly chart with its five-week MMA at $115.50 while Pfizer has a negative weekly chart with its five-week MMA at $29.97. The technicals thus favor Amgen over Pfizer.
Amgen has a semiannual value level at $102.54 with a monthly risky level at $122.38. Pfizer has an annual value level at $23.35 with semiannual pivots at $28.78 and $29.20 with a monthly risky level at $33.10.
Barclays (BCS) ($16.19) is below its 200-day SMA at $16.62 and has a negative weekly chart with its five-week MMA at $16.57 and 200-week SMA at $15.07. Semiannual; value levels are $13.70 and $12.74 with a quarterly pivot at $16.61 and monthly risky level at $17.06. Good endorsement, sell the stock.
Exxon Mobil (XOM) ($100.23) set an all-time intraday high at $103.45 on May 7 but its weekly chart shifts to negative given a close this week below its five-week MMA at $100.04. A semiannual value level is $91.91 with a semiannual pivot at $100.97 with an annual risky level at $108.71. Use the fuel, sell the stock.
At the time of publication the author held no positions in any of the stocks mentioned.
This article represents the opinion of a contributor and not necessarily that of TheStreet or its editorial staff
>>Read more: Where to Buy Dad a Cheap iPhone for Father's Day